In summary, our research suggests that a high level of Shp2 indicates reduced sensitivity to cisplatin in SCLC and that inhibiting Shp2 expression can restore the sensitivity of SCLC to cisplatin. This evidence concerns the gene PTPN11 and small cell lung carcinoma.